Heatwurx (PCSA) Competitors

$2.66 -0.02 (-0.75%)

Closing price 04:00 PM Eastern

Extended Trading

$2.73 +0.07 (+2.59%)

As of 05:22 PM Eastern

PCSA vs. PLRZ, ALVR, SNTI, CELU, and TVRD

Should you be buying Heatwurx stock or one of its competitors? The main competitors of Heatwurx include Polyrizon (PLRZ), AlloVir (ALVR), Senti Biosciences (SNTI), Celularity (CELU), and Tvardi Therapeutics (TVRD). These companies are all part of the "pharmaceutical products" industry.

How does Heatwurx compare to Polyrizon?

Polyrizon (NASDAQ:PLRZ) and Heatwurx (NASDAQ:PCSA) are both small-cap medical companies, but which is the superior business? We will contrast the two companies based on the strength of their dividends, valuation, analyst recommendations, media sentiment, risk, profitability, institutional ownership and earnings.

: Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio
Polyrizon N/A N/A -$3.34M N/A N/A
Heatwurx N/A N/A -$13.56M -$34.00 N/A
: In the previous week, Heatwurx had 1 more articles in the media than Polyrizon. MarketBeat recorded 5 mentions for Heatwurx and 4 mentions for Polyrizon. Heatwurx's average media sentiment score of 1.00 beat Polyrizon's score of 0.18 indicating that Heatwurx is being referred to more favorably in the news media.
Company Overall Sentiment
Polyrizon Neutral
Heatwurx Positive
: Polyrizon has a beta of -2.04, meaning that its share price is 304% less volatile than the S&P 500. Comparatively, Heatwurx has a beta of 1.01, meaning that its share price is 1% more volatile than the S&P 500.
: Polyrizon's return on equity of 0.00% beat Heatwurx's return on equity.
Company Net Margins Return on Equity Return on Assets
Polyrizon N/A N/A N/A
Heatwurx N/A -257.81% -191.10%
: 91.9% of Heatwurx shares are owned by institutional investors. 2.4% of Heatwurx shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock will outperform the market over the long term.
: Heatwurx has a consensus price target of $25.00, indicating a potential upside of 839.85%. Given Heatwurx's stronger consensus rating and higher possible upside, analysts plainly believe Heatwurx is more favorable than Polyrizon.
Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Polyrizon
1 Sell rating(s)
0 Hold rating(s)

0 Buy rating(s)

0 Strong Buy rating(s)
1.00
Heatwurx
1 Sell rating(s)

1 Hold rating(s)

1 Buy rating(s)

0 Strong Buy rating(s)
2.00

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Polyrizon	N/A	N/A	-$3.34M	N/A	N/A
Heatwurx	N/A	N/A	-$13.56M	-$34.00	N/A

Company	Overall Sentiment
Polyrizon	Neutral
Heatwurx	Positive

Company	Net Margins	Return on Equity	Return on Assets
Polyrizon	N/A	N/A	N/A
Heatwurx	N/A	-257.81%	-191.10%

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Polyrizon	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
Heatwurx	1 Sell rating(s)	1 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00

Summary

Heatwurx beats Polyrizon on 8 of the 11 factors compared between the two stocks.

How does Heatwurx compare to AlloVir?

AlloVir (NASDAQ:ALVR) and Heatwurx (NASDAQ:PCSA) are both small-cap medical companies, but which is the superior business? We will compare the two companies based on the strength of their profitability, valuation, risk, dividends, earnings, analyst recommendations, institutional ownership and media sentiment.

: Heatwurx has a consensus price target of $25.00, indicating a potential upside of 839.85%. Given Heatwurx's stronger consensus rating and higher possible upside, analysts clearly believe Heatwurx is more favorable than AlloVir.
Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
AlloVir
0 Sell rating(s)
0 Hold rating(s)

0 Buy rating(s)

0 Strong Buy rating(s)
0.00
Heatwurx
1 Sell rating(s)

1 Hold rating(s)

1 Buy rating(s)

0 Strong Buy rating(s)
2.00
: In the previous week, Heatwurx had 5 more articles in the media than AlloVir. MarketBeat recorded 5 mentions for Heatwurx and 0 mentions for AlloVir. Heatwurx's average media sentiment score of 1.00 beat AlloVir's score of 0.00 indicating that Heatwurx is being referred to more favorably in the news media.
Company Overall Sentiment
AlloVir Neutral
Heatwurx Positive
: 66.1% of AlloVir shares are held by institutional investors. Comparatively, 91.9% of Heatwurx shares are held by institutional investors. 32.1% of AlloVir shares are held by company insiders. Comparatively, 2.4% of Heatwurx shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth.
: AlloVir has a beta of 0.63, meaning that its stock price is 37% less volatile than the S&P 500. Comparatively, Heatwurx has a beta of 1.01, meaning that its stock price is 1% more volatile than the S&P 500.
: AlloVir is trading at a lower price-to-earnings ratio than Heatwurx, indicating that it is currently the more affordable of the two stocks.
Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio
AlloVir N/A N/A -$190.42M -$20.23 N/A
Heatwurx N/A N/A -$13.56M -$34.00 N/A
: AlloVir's return on equity of -71.03% beat Heatwurx's return on equity.
Company Net Margins Return on Equity Return on Assets
AlloVir N/A -71.03% -61.27%
Heatwurx N/A -257.81% -191.10%

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
AlloVir	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00
Heatwurx	1 Sell rating(s)	1 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00

Company	Overall Sentiment
AlloVir	Neutral
Heatwurx	Positive

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
AlloVir	N/A	N/A	-$190.42M	-$20.23	N/A
Heatwurx	N/A	N/A	-$13.56M	-$34.00	N/A

Company	Net Margins	Return on Equity	Return on Assets
AlloVir	N/A	-71.03%	-61.27%
Heatwurx	N/A	-257.81%	-191.10%

Summary

Heatwurx beats AlloVir on 9 of the 13 factors compared between the two stocks.

How does Heatwurx compare to Senti Biosciences?

Senti Biosciences (NASDAQ:SNTI) and Heatwurx (NASDAQ:PCSA) are both small-cap medical companies, but which is the superior investment? We will compare the two businesses based on the strength of their valuation, institutional ownership, analyst recommendations, media sentiment, profitability, earnings, dividends and risk.

: 25.7% of Senti Biosciences shares are held by institutional investors. Comparatively, 91.9% of Heatwurx shares are held by institutional investors. 3.1% of Senti Biosciences shares are held by company insiders. Comparatively, 2.4% of Heatwurx shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock is poised for long-term growth.
: In the previous week, Heatwurx had 4 more articles in the media than Senti Biosciences. MarketBeat recorded 5 mentions for Heatwurx and 1 mentions for Senti Biosciences. Heatwurx's average media sentiment score of 1.00 beat Senti Biosciences' score of 0.00 indicating that Heatwurx is being referred to more favorably in the news media.
Company Overall Sentiment
Senti Biosciences Neutral
Heatwurx Positive
: Senti Biosciences currently has a consensus price target of $8.50, suggesting a potential upside of 790.99%. Heatwurx has a consensus price target of $25.00, suggesting a potential upside of 839.85%. Given Heatwurx's higher probable upside, analysts clearly believe Heatwurx is more favorable than Senti Biosciences.
Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Senti Biosciences
1 Sell rating(s)
0 Hold rating(s)

3 Buy rating(s)

1 Strong Buy rating(s)
2.80
Heatwurx
1 Sell rating(s)

1 Hold rating(s)

1 Buy rating(s)

0 Strong Buy rating(s)
2.00
: Heatwurx has lower revenue, but higher earnings than Senti Biosciences. Senti Biosciences is trading at a lower price-to-earnings ratio than Heatwurx, indicating that it is currently the more affordable of the two stocks.
Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio
Senti Biosciences $20K 1,485.38 -$61.44M -$3.19 N/A
Heatwurx N/A N/A -$13.56M -$34.00 N/A
: Heatwurx's return on equity of -257.81% beat Senti Biosciences' return on equity.
Company Net Margins Return on Equity Return on Assets
Senti Biosciences N/A -301.48% -90.03%
Heatwurx N/A -257.81% -191.10%
: Senti Biosciences has a beta of 2.09, meaning that its stock price is 109% more volatile than the S&P 500. Comparatively, Heatwurx has a beta of 1.01, meaning that its stock price is 1% more volatile than the S&P 500.

Company	Overall Sentiment
Senti Biosciences	Neutral
Heatwurx	Positive

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Senti Biosciences	1 Sell rating(s)	0 Hold rating(s)	3 Buy rating(s)	1 Strong Buy rating(s)	2.80
Heatwurx	1 Sell rating(s)	1 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Senti Biosciences	$20K	1,485.38	-$61.44M	-$3.19	N/A
Heatwurx	N/A	N/A	-$13.56M	-$34.00	N/A

Company	Net Margins	Return on Equity	Return on Assets
Senti Biosciences	N/A	-301.48%	-90.03%
Heatwurx	N/A	-257.81%	-191.10%

Summary

Senti Biosciences beats Heatwurx on 8 of the 15 factors compared between the two stocks.

How does Heatwurx compare to Celularity?

Heatwurx (NASDAQ:PCSA) and Celularity (NASDAQ:CELU) are both small-cap medical companies, but which is the better investment? We will compare the two businesses based on the strength of their earnings, risk, dividends, media sentiment, valuation, institutional ownership, profitability and analyst recommendations.

: In the previous week, Heatwurx had 3 more articles in the media than Celularity. MarketBeat recorded 5 mentions for Heatwurx and 2 mentions for Celularity. Heatwurx's average media sentiment score of 1.00 beat Celularity's score of 0.20 indicating that Heatwurx is being referred to more favorably in the media.
Company Overall Sentiment
Heatwurx Positive
Celularity Neutral
: 91.9% of Heatwurx shares are owned by institutional investors. Comparatively, 19.0% of Celularity shares are owned by institutional investors. 2.4% of Heatwurx shares are owned by insiders. Comparatively, 17.3% of Celularity shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term.
: Heatwurx currently has a consensus target price of $25.00, suggesting a potential upside of 839.85%. Celularity has a consensus target price of $6.00, suggesting a potential upside of 536.94%. Given Heatwurx's higher probable upside, equities analysts clearly believe Heatwurx is more favorable than Celularity.
Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Heatwurx
1 Sell rating(s)
1 Hold rating(s)

1 Buy rating(s)

0 Strong Buy rating(s)
2.00
Celularity
1 Sell rating(s)

0 Hold rating(s)

1 Buy rating(s)

0 Strong Buy rating(s)
2.00
: Heatwurx has higher earnings, but lower revenue than Celularity. Celularity is trading at a lower price-to-earnings ratio than Heatwurx, indicating that it is currently the more affordable of the two stocks.
Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio
Heatwurx N/A N/A -$13.56M -$34.00 N/A
Celularity $54.22M 0.50 -$57.89M -$3.33 N/A
: Heatwurx has a beta of 1.01, suggesting that its share price is 1% more volatile than the S&P 500. Comparatively, Celularity has a beta of 0.44, suggesting that its share price is 56% less volatile than the S&P 500.
: Heatwurx has a net margin of 0.00% compared to Celularity's net margin of -198.75%. Celularity's return on equity of 0.00% beat Heatwurx's return on equity.
Company Net Margins Return on Equity Return on Assets
Heatwurx N/A -257.81% -191.10%
Celularity -198.75% N/A -65.03%

Company	Overall Sentiment
Heatwurx	Positive
Celularity	Neutral

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Heatwurx	1 Sell rating(s)	1 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00
Celularity	1 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Heatwurx	N/A	N/A	-$13.56M	-$34.00	N/A
Celularity	$54.22M	0.50	-$57.89M	-$3.33	N/A

Company	Net Margins	Return on Equity	Return on Assets
Heatwurx	N/A	-257.81%	-191.10%
Celularity	-198.75%	N/A	-65.03%

Summary

Heatwurx beats Celularity on 8 of the 13 factors compared between the two stocks.

How does Heatwurx compare to Tvardi Therapeutics?

Heatwurx (NASDAQ:PCSA) and Tvardi Therapeutics (NASDAQ:TVRD) are both small-cap medical companies, but which is the superior investment? We will contrast the two companies based on the strength of their earnings, media sentiment, dividends, profitability, institutional ownership, analyst recommendations, risk and valuation.

: In the previous week, Heatwurx had 5 more articles in the media than Tvardi Therapeutics. MarketBeat recorded 5 mentions for Heatwurx and 0 mentions for Tvardi Therapeutics. Heatwurx's average media sentiment score of 1.00 beat Tvardi Therapeutics' score of 0.00 indicating that Heatwurx is being referred to more favorably in the media.
Company Overall Sentiment
Heatwurx Positive
Tvardi Therapeutics Neutral
: 91.9% of Heatwurx shares are held by institutional investors. Comparatively, 44.7% of Tvardi Therapeutics shares are held by institutional investors. 2.4% of Heatwurx shares are held by company insiders. Comparatively, 3.1% of Tvardi Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term.
: Heatwurx currently has a consensus target price of $25.00, suggesting a potential upside of 839.85%. Tvardi Therapeutics has a consensus target price of $55.50, suggesting a potential upside of 1,404.07%. Given Tvardi Therapeutics' stronger consensus rating and higher possible upside, analysts clearly believe Tvardi Therapeutics is more favorable than Heatwurx.
Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Heatwurx
1 Sell rating(s)
1 Hold rating(s)

1 Buy rating(s)

0 Strong Buy rating(s)
2.00
Tvardi Therapeutics
1 Sell rating(s)

3 Hold rating(s)

3 Buy rating(s)

1 Strong Buy rating(s)
2.50
: Tvardi Therapeutics is trading at a lower price-to-earnings ratio than Heatwurx, indicating that it is currently the more affordable of the two stocks.
Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio
Heatwurx N/A N/A -$13.56M -$34.00 N/A
Tvardi Therapeutics N/A N/A -$18.21M -$5.59 N/A
: Heatwurx has a beta of 1.01, meaning that its stock price is 1% more volatile than the S&P 500. Comparatively, Tvardi Therapeutics has a beta of 0.3, meaning that its stock price is 70% less volatile than the S&P 500.
: Tvardi Therapeutics' return on equity of -73.53% beat Heatwurx's return on equity.
Company Net Margins Return on Equity Return on Assets
Heatwurx N/A -257.81% -191.10%
Tvardi Therapeutics N/A -73.53% -35.22%

Company	Overall Sentiment
Heatwurx	Positive
Tvardi Therapeutics	Neutral

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Heatwurx	1 Sell rating(s)	1 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00
Tvardi Therapeutics	1 Sell rating(s)	3 Hold rating(s)	3 Buy rating(s)	1 Strong Buy rating(s)	2.50

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Heatwurx	N/A	N/A	-$13.56M	-$34.00	N/A
Tvardi Therapeutics	N/A	N/A	-$18.21M	-$5.59	N/A

Company	Net Margins	Return on Equity	Return on Assets
Heatwurx	N/A	-257.81%	-191.10%
Tvardi Therapeutics	N/A	-73.53%	-35.22%

Summary

Tvardi Therapeutics beats Heatwurx on 8 of the 14 factors compared between the two stocks.

Get Heatwurx News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding PCSA and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

PCSA vs. The Competition

Export

Metric	Heatwurx	MED Industry	Medical Sector	NASDAQ Exchange
Market Cap	$7.08M	$3.10B	$6.25B	$11.87B
Dividend Yield	N/A	1.91%	2.73%	5.21%
P/E Ratio	-0.08	18.37	29.04	28.47
Price / Sales	N/A	281.30	476.61	60.92
Price / Cash	N/A	50.43	27.62	36.52
Price / Book	1.08	4.33	9.67	6.67
Net Income	-$13.56M	$72.19M	$3.55B	$332.53M
7 Day Performance	-6.67%	2.03%	1.70%	2.01%
1 Month Performance	-3.97%	6.42%	5.62%	9.19%
1 Year Performance	-56.78%	37.73%	34.41%	39.59%

Heatwurx Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
PCSA Heatwurx	3.1299 of 5 stars	$2.66 -0.7%	$25.00 +839.8%	N/A	$7.08M	N/A	N/A	20	Positive News
PLRZ Polyrizon	0.3126 of 5 stars	$16.61 -0.1%	N/A	N/A	$31.06M	N/A	N/A	N/A	News Coverage Analyst Upgrade Gap Down
ALVR AlloVir	N/A	$6.02 -1.5%	N/A	N/A	$30.36M	N/A	N/A	110
SNTI Senti Biosciences	2.5988 of 5 stars	$0.96 -9.6%	$8.50 +787.3%	N/A	$29.84M	$22K	N/A	4
CELU Celularity	1.6052 of 5 stars	$1.03 +4.1%	$6.00 +482.0%	N/A	$29.73M	$54.22M	N/A	220	Earnings Report Upcoming Earnings

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:PCSA) was last updated on 5/5/2026 by MarketBeat.com Staff.

From Our Partners

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Heatwurx (PCSA) Competitors